Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled time : 14:20 save search
Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
Published: 2023-07-25 (Crawled : 14:20) - globenewswire.com
NYMX | $0.2 -19.68% -23.88% 930K
|
Health Technology
| Email alert
Add to watchlist
cancer treatment trial results
hC Bioscience Appoints Heather Hirsch, Ph.D. as SVP of Translational Science and Cancer Biology, Strengthening Leadership Team in Advancing tRNA-Based Therapeutics
Published: 2023-07-18 (Crawled : 14:20) - biospace.com/
IMVIQ | $0.0001 36400.0% 6K
|
Manufacturing
|
| O: 20.0%
H: 46.67%
C: -33.33%
bioscience cancer therapeutics
Zhongchao Inc. Partners with Ximalaya to Launch the First Audio Course Series for Cancer Education
Published: 2023-07-11 (Crawled : 14:20) - biospace.com/
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
|
| O: -1.67%
H: 11.0%
C: 8.55%
cancer audio education
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
Published: 2023-06-15 (Crawled : 14:20) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.31%
H: 0.78%
C: 0.69%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 2.46%
H: 9.6%
C: 5.6%
authorization cancer application
Libtayo (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer
Published: 2023-05-01 (Crawled : 14:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.08%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
lung approved cancer cell treatment libtayo canada
Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention
Published: 2022-11-09 (Crawled : 14:20) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: 3.6%
H: 0.0%
C: -4.35%
cancer
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer
Published: 2023-02-06 (Crawled : 14:20) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: -0.59%
H: 11.31%
C: 5.36%
test breast genetic cancer risk
Back-to-back Studies Validate geneType Breast Cancer Risk Test
Published: 2023-03-13 (Crawled : 14:20) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: 0.0%
H: 6.31%
C: 4.5%
test breast cancer risk
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
Published: 2023-04-26 (Crawled : 14:20) - globenewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -4.57%
H: 0.22%
C: -1.98%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.03%
H: 0.3%
C: -2.63%
ZNTL | $12.97 3.43% 3.32% 1M
|
Health Technology
|
| O: -0.23%
H: 0.18%
C: -1.43%
asco positive cancer meeting
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
Published: 2023-04-20 (Crawled : 14:20) - biospace.com/
SLRX | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: -8.6%
H: 1.76%
C: -2.35%
sp-3164 association cancer pharmaceuticals research protein meeting
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
Published: 2023-04-19 (Crawled : 14:20) - globenewswire.com
HOWL | $5.91 0.68% 0.68% 120K
|
Professional, Scientific, and T...
|
| O: -2.73%
H: 5.27%
C: -0.8%
wtx-330 cancer research preclinical immunology therapeutics il-12
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
Published: 2023-04-17 (Crawled : 14:20) - globenewswire.com
ALLO | $3.48 0.58% 0.57% 2M
|
Health Technology
|
| O: 1.0%
H: 7.54%
C: -3.97%
allo-316 association renal cancer cell research meeting therapeutics
NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
NEO | $13.54 -1.67% -1.7% 770K
|
Health Services
|
| O: -0.07%
H: 1.28%
C: 0.74%
association cancer research meeting
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
RVMD S | $34.95 -2.46% -2.52% 1.2M
|
Health Technology
|
| O: 0.29%
H: 1.12%
C: 0.0%
association cancer research preclinical meeting
Tonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-05 (Crawled : 14:20) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 2.88%
H: 0.0%
C: 0.0%
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: -0.07%
H: 5.37%
C: 4.04%
association cancer pharmaceuticals research meeting
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
Published: 2023-03-28 (Crawled : 14:20) - biospace.com/
PPCB | $0.001 -41.86% 11M
|
Manufacturing
|
| O: 0.0%
H: 40.0%
C: 20.0%
cancer pancreatic biopharma tumor
Pfizer and Astellas Seek Expanded Label for Expensive Prostate Cancer Drug
Published: 2023-03-17 (Crawled : 14:20) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.29%
H: 0.3%
C: -1.36%
drug label cancer
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Published: 2023-03-16 (Crawled : 14:20) - biospace.com/
XBIO | $4.14 7.32% 770
|
Health Technology
|
| O: 5.13%
H: 9.76%
C: 3.54%
cancer
Hoag Unveils Newly Expanded Patty & George Hoag Cancer Center
Published: 2023-02-23 (Crawled : 14:20) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
cancer
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
Published: 2023-02-23 (Crawled : 14:20) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 0.0%
H: 6.94%
C: 2.85%
women breast cancer study her2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.